Research Papers:

Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes

Qi Wu, Juanjuan Li, Si Sun, Shan Zhu, Chuang Chen, Juan Wu, Qian Liu, Wen Wei and Shengrong Sun _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:2361-2371. https://doi.org/10.18632/oncotarget.13785

Metrics: PDF 2006 views  |   HTML 2356 views  |   ?  


Qi Wu1, Juanjuan Li1, Si Sun2, Shan Zhu1, Chuang Chen1, Juan Wu3, Qian Liu1, Wen Wei1 and Shengrong Sun1

1 Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, P. R. China

2 Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei, P. R. China

3 Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, Hubei, P. R. China

Correspondence to:

Shengrong Sun, email:

Keywords: breast carcinoma in situ, tumor subtype, treatment, outcomes

Received: September 14, 2016 Accepted: November 23, 2016 Published: December 02, 2016


Background & Aims: To evaluate the clinical presentation, treatment and outcome of patients with breast carcinoma in situ (BCIS) with special emphasis on the role of the tumor subtype and local treatment in these patients.

Methods: Using data obtained by the Surveillance, Epidemiology, and End Results (SEER) program from 2010-2013, a retrospective, population-based cohort study was conducted to investigate tumor subtype-specific differences in various characteristics, overall survival (OS) and breast cancer-specific mortality (BCSM).

Results: In all, 6867 patients with BCIS were eligible during the 2010-2013 study period. Compared with the hormone receptor (HoR)+/HER- subgroup, patients with triple negative (TN) breast cancer were more likely to have tumors that were higher in grade and larger in size; they were also more likely to have tumors with ductal and comedo histology and were less likely to have tumors with cribriform and papillary histology (each P < 0.05). During the follow-up period, patients with TN breast cancer had an OS of 97.0% compared with 98.6 % in the HoR+/HER- subgroup (P < 0.05). Furthermore, the BCSM rate was 1.0% for the TN group compared with 0.1% for the HoR+/HER- subgroup (P < 0.05). Multivariate analysis revealed that patients with TN MBC had a poorer OS and BCSM (P <0.05). Multivariate analysis of OS with respect to the local treatment history showed that patients who received breast-conserving surgery (BCS) combined with radiotherapy (R) were more likely to have an improved OS (P < 0.05). Moreover, the results demonstrated that patients who underwent SLNB were more likely to have a lower BCSM (P < 0.05).

Conclusions: The results demonstrate that BCIS appears to alter the prognosis associated with the TN subtype. Meanwhile, BCS plus R was a preferable option and resulted in survival rates that were better than those achieved with mastectomy; thus, SLNB should be considered as an appropriate assessment of axillary staging in patients with BCIS.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13785